(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
1.41% ¥ 1 512.50
Live Chart Being Loaded With Signals
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial...
Stats | |
---|---|
Объем за сегодня | 2.72M |
Средний объем | 1.50M |
Рыночная капитализация | 531.20B |
EPS | ¥0 ( 2024-02-07 ) |
Дата следующего отчета о доходах | ( ¥13.64 ) 2024-05-08 |
Last Dividend | ¥16.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 20.28 |
ATR14 | ¥0.772 (0.05%) |
Объем Корреляция
Santen Pharmaceutical Корреляция
10 Самые положительные корреляции |
---|
10 Самые отрицательные корреляции |
---|
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Santen Pharmaceutical Корреляция - Валюта/Сырье
Santen Pharmaceutical Финансовые показатели
Annual | 2022 |
Выручка: | ¥279.04B |
Валовая прибыль: | ¥166.09B (59.52 %) |
EPS: | ¥-38.58 |
FY | 2022 |
Выручка: | ¥279.04B |
Валовая прибыль: | ¥166.09B (59.52 %) |
EPS: | ¥-38.58 |
FY | 2022 |
Выручка: | ¥266.26B |
Валовая прибыль: | ¥156.59B (58.81 %) |
EPS: | ¥68.07 |
FY | 2021 |
Выручка: | ¥249.61B |
Валовая прибыль: | ¥151.38B (60.65 %) |
EPS: | ¥17.09 |
Financial Reports:
No articles found.
Santen Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥16.00 (N/A) |
¥0 (N/A) |
¥16.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥2.00 | 2001-03-27 |
Last Dividend | ¥16.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 46 | -- |
Total Paid Out | ¥423.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.84 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.72 | |
Div. Directional Score | 7.93 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8068.T | Ex Dividend Knight | 2024-01-30 | Semi-Annually | 0 | 0.00% | |
7350.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6590.T | Ex Dividend Knight | 2024-03-28 | Annually | 0 | 0.00% | |
5936.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
4617.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3852.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
3093.T | Ex Dividend Knight | 2024-02-28 | Semi-Annually | 0 | 0.00% | |
1967.T | Ex Dividend Junior | 2024-03-18 | Annually | 0 | 0.00% | |
9982.T | Ex Dividend Knight | 2024-02-28 | Semi-Annually | 0 | 0.00% | |
8966.T | Ex Dividend Knight | 2023-11-29 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0918 | 1.500 | 8.16 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0648 | 1.200 | 7.84 | 9.41 | [0 - 0.3] |
returnOnEquityTTM | 0.0924 | 1.500 | -0.0848 | -0.127 | [0.1 - 1] |
payoutRatioTTM | 0.429 | -1.000 | 5.71 | -5.71 | [0 - 1] |
currentRatioTTM | 2.46 | 0.800 | 2.72 | 2.17 | [1 - 3] |
quickRatioTTM | 1.841 | 0.800 | 3.88 | 3.10 | [0.8 - 2.5] |
cashRatioTTM | 0.897 | 1.500 | 6.13 | 9.19 | [0.2 - 2] |
debtRatioTTM | 0.0786 | -1.500 | 8.69 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 20.13 | 1.000 | 3.66 | 3.66 | [3 - 30] |
operatingCashFlowPerShareTTM | 192.60 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 162.21 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.113 | -1.500 | 9.55 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.606 | 1.000 | 3.24 | 3.24 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.143 | 1.000 | 9.14 | 9.14 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 2.03 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.706 | 0.800 | 8.63 | 6.90 | [0.5 - 2] |
Total Score | 11.14 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 19.29 | 1.000 | 8.15 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0924 | 2.50 | -0.0545 | -0.127 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 162.21 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.18 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 192.60 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.429 | 1.500 | 5.71 | -5.71 | [0 - 1] |
pegRatioTTM | -0.123 | 1.500 | -4.15 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.225 | 1.000 | 6.86 | 0 | [0.1 - 0.5] |
Total Score | 4.72 |
Santen Pharmaceutical
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа